文献发表
沙砾生物研发团队在国际知名学术期刊发表多项研究成果，推动细胞治疗领域的科学进步
2025 年
High-fidelity AaCas12bMax enables the development of an engineered T cell therapy with enhanced safety and functional fitness
Jingwei Sun, Ke Liu, Yao Sheng, Hongwei Zhang, Jingman Wang, Yueqiang Wang, Rui Tian, Xi Zhu, Shin-Shay Tian, Pin Wang, Xiaoping Zhao, Yarong Liu
Engineering DNA Origami Captors for TGF-β1 Sequestration to Enhance Tumor Immune Modulation and Therapy
Xiao Chen, Dunfang Liu, Jiahui Jin, Han Yao, Yao Sheng, Yarong Liu, Jingwei Sun, Yang Yang
2024 年
T cell receptor repertoire characteristics and therapeutic potential of tumor-infiltrating lymphocytes (TILs) derived from metastatic lymph node in cervical cancer
Xuan Zhao, Zhenjiang Liu, Haifeng Qin, Yarong Liu, Yi Zhang
A genetically modified tumor-infiltrating lymphocytes product (GT216) enhanced anti-tumor efficacy against solid tumor by fine-tuning multiple negative immune regulators
Jingwei Sun,Yiyang Tan,Jiahui Jin,Jingman Wang, Lingyun Chen, Fengbiao Guo,Yongchao Tan,Zhao Xu,Yarong Liu
A CRISPR/Cas9 screening platform ImmuT Finder® enables in vivo T cell functional screening and identification of potent immunoregulatory targets for next-generation T cell therapy
Jingwei Sun,Jiahui Jin,Jingman Wang,Yao Sheng,Fei Li,Lingyun Chen,Yongchao Tan,Zhao Xu,Yanbin Liu,Ke Liu,Yarong Liu
Generation of tumor-reactive T cells by co-culture of tumor-infiltrating lymphocytes (TILs) and patient-derived organoids (PDOs)
Zhenjiang Liu,Jingwei Sun,Xinyu Gao,Xu Wang,Ke Liu,Chao Ni,Pin Wang,Bing Zhao,Yarong Liu
Trial in Progress: First-in-Human Study of Next-Generation Dual-KO TIL Therapy GT300 in Patients with Advanced Solid Tumors
Yarong Liu,Yu Jing,Lili Lu,Liqing Ma,Jingwei Sun,Pin Wang
Development of a next-generation dual-KO TIL product GT300 with AaCas12bMax nuclease
Jingwei Sun,Yao Sheng,Hongwei Zhang,Xi Zhu,Jingman Wang,Ke Liu,Shin-Shay Tian,Pin Wang,Xiaoping Zhao,Yarong Liu
Phase 1 Study of GT101 as an Autologous Tumor Infiltrating Lymphocyte Therapy in Advanced Solid Tumors
Haifeng Qin, Yongsheng Wang, Yuyao Yi, Fang Gao, Dongling Zou, Yongsheng Li, Xiubao Ren, Dongmei Ji, Jian Zhang, Shasha Wang, Zhen Zeng, Jing Yu, Liqing Ma, Yishan Liu, Lili Lu, Derun Shen, Xue Zhai, Pin Wang, and Yarong Liu
A first-in-human study of CRISPR/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors
Jing Guo, Wei Huang, Binghui Zhao, Jing Yu, Jun Cui, Jingwei Sun, Liqing Ma, Yishan Liu, Derun Shen, Lin Shen, Pin Wang, Yarong Liu, and Zhongping Cheng
Exploring the Safety and Efficacy of GT201 as a First-in-Class Autologous Tumor-Infiltrating Lymphocyte Monotherapy in Advanced Solid Tumors
Zhengxiang Han, Weijia Fang, Kai Chen, Youguo Chen, Hongmei Wang, Juanjuan Tang, Jing Yu, Liqing Ma, Yishan Liu, Lili Lu, Derun Shen, Xue Zhai, Pin Wang, and Yarong Liu
Unleashing the Potential of NK Cell Therapy by Genetic Disruption of Key Immunoregulators Identified via ImmuT Finder® Platform
Grit Bio
The Discovery and Development of GT316 as a CRISPR/Cas9-Dual KO Anti-Exhaustion TIL Product for Advanced Solid Tumors
Yarong Liu,Jingwei Sun,Yao Sheng,Jingman Wang,Jiahui Jin,Fei Li,Lingyun Chen,Di Zhou,Yongchao Tan,Quanwei Wang,Zhao Xu,Haibao Li,Pin Wang,Jun Cui
2023 年
Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy
Hao Feng, Ling Qiu, Zixiao Shi, Yao Sheng, Peipei Zhao, Di Zhou, Fei Li, Hailin Yu, Yanan You, Hui Wang, Ming Li, Shurong Zhu, Yan Du, Jun Cui, Jingwei Sun, Yarong Liu, Hua Jiang, Xin Wu
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
Yanbin Liu, Zhenjiang Liu, Yixiao Yang, Jun Cui, Jingwei Sun, Yarong Liu
A Functionally Enhanced Tumor-Infiltrating Lymphocytes Product (GT201) Exhibits Improved Persistence and Anti-Tumor Efficacy With Low IL-2 Dependency
Grit Bio
Distinct predictive value of CD137 as a tumor reactive marker among different cancer types and TIL expansion stage
Zhenjiang Liu,Jingwei Sun,Zixiao Shi,Peipei Zhao,Quanwei Wang,Xu Wang,Pin Wang,Yarong Liu
The discovery and development of a CRISPR/Cas9-engineered tumor-infiltrating lymphocytes product (GT316) as a next-generation TIL therapy
Yarong Liu, Jingwei Sun,Yao Sheng,Jingman Wang,Jiahui Jin,Fei L,Lingyun Chen,Di Zhou,Yongchao Tan,Quanwei Wang,Zhao Xu,Haibao Li,Pin Wang,Jun Cui
2022 年
A genetically modified tumor-infiltrating lymphocytes product (GT202) exhibits enhanced persistence and anti-tumor efficacy against solid tumor in vivo
Jingwei Sun,Jiahui Jin,Yongchao Tan,Lingyun Chen,Quanwei Wang,Yarong Liu
Modulation of intracellular kinase signaling to improve TIL manufacturing for adoptive cell therapy
Zixiao Shi,Sheng Yao,Peipei Zhao,Fei Li,Di Zhou,Jun Cui,Jingwei Sun,Yarong Liu
2021 年
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
Shuhang Wang, Jingwei Sun, Kun Chen, Peiwen Ma, Qi Lei, Shujun Xing, Zhongzheng Cao, Shujun Sun, Zicheng Yu, Yarong Liu, Ning Li
The Landscape of Cell and Gene Therapies for Solid Tumors
Shuhang Wang, Fa Sun, Huiyao Huang, Kun Chen, Qi-Jing Li, Lu Zhang, Enxiu Wang, Chen Wang, Hai Zhang, Andy Qingan Yuan, Bin Chen, Tao Deng, Yarong Liu, Jingwei Sun, Dongfang Liu, Yue Yu, Yuan Fang, Ning Jiang, Dawei Wu, Hong Fang, Ying Bai, Shujun Xing, Yufen Ni, Qi Fan, Anqi Yu, Chao Sun, Yu Tang, Ning Li, Binghe Xu, Jie He
《细胞治疗》专著
主编：王明伟；副主编：王方敏、贾国栋、吴健、郝好杰；编委：丁佳、王华、王钰、王方敏、王立群、王明伟、史春梦、任艺虹、刘雅容等
2020 年
The toxicity of cell therapy: Mechanism, manifestations, and challenges
Yongjia Jin, Yan Dong, Jin Zhang, Jingwei Sun, Yarong Liu, Yong Chen